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Abstract
In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies
has dramatically improved the clinical outcomes for patients with advanced melanoma. These antagonist monoclonal
antibodies are capable of unleashing dormant or exhausted antitumor immunity, which has led to durable complete
and partial responses in a large number of patients. Ipilimumab targets the cytotoxic T lymphocyte-associated protein 4
(CTLA-4) receptor. Nivolumab and pembrolizumab target programmed cell death protein 1 (PD-1) receptors and
have proven to be superior to ipilimumab alone. The combination of ipilimumab and nivolumab has yielded
higher response rates, greater tumor shrinkage, and longer progression-free survival than either monotherapy
alone. As other promising immunotherapies for melanoma proceed through clinical trials, future goals include
defining the role of immune checkpoint inhibitors as adjuvant therapy, identifying optimal combination strategies, and
developing reliable predictive biomarkers to guide treatment selection for individual patients.
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Background
Advanced melanoma has historically been associated with
a poor prognosis, with a median overall survival (OS) of
8–10 months and a 5-year survival rate of 10 % [1].
Chemotherapy clinical trials produced modest benefit to
patients, with short-lived objective responses typically seen
in less than 15 % of patients [2]. Initial studies in the
1980s demonstrated the ability of interleukin-2 (IL-2) to
mediate tumor regression in melanoma and other malig-
nancies [3]. In addition, it was recognized that patients
with melanoma tumors infiltrated with T cells had better
long-term survival, potentially as a result of an active anti-
tumor response by the immune system, which led to
therapeutic approaches using recombinant high-dose IL-2
to induce immune-mediated tumor cell lysis in patients
with metastatic melanoma [4, 5]. Pooled data from pa-
tients treated at the National Cancer Institute and within
the Extramural IL-2 Working Group demonstrated object-
ive responses in 16 % of patients treated with high-dose
IL-2 [6], of which, nearly half were durable or permanent,
suggesting that long-term survival or ‘cure’ is possible.
However, IL-2 is associated with a number of serious tox-
icities, largely related to vascular leak syndrome, requiring
inpatient management at experienced centers. While these
factors have limited its generalized use, high-dose IL-2
serves as proof of principle that immunotherapies can
eliminate tumor cells in some patients, encouraging efforts
to develop better tolerated and more effective immuno-
therapy regimens.
In order to achieve antitumor effects, cytotoxic T
lymphocytes (CTL) must not only migrate to the tumor,
but must also be capable of tumor cell lysis. While the
presence of tumor infiltrating lymphocytes (TIL) is
frequently seen in melanoma tumors, TILs often have a di-
minished capacity for proliferation, cytokine production,
and tumor lysis [7]. However, when TILs are removed
from the tumor microenvironment (TME) and grown
ex vivo, they can exhibit potent and specific antitumor
activity, implying that the immune climate within the
TME can dampen CTL activity. Evidence suggests that
inflammation caused by immune infiltration can induce
immune escape mechanisms, including interferon (IFN)-
gamma-mediated upregulation of programmed death-
ligand 1 (PD-L1) in the TME and increased numbers of
regulatory T cells (Tregs) [8]. The engagement of PD-L1
(and PD-L2) with the programmed cell death protein 1
(PD-1) receptor on CTL leads to T cell exhaustion. Anti-
bodies to PD-1 or PD-L1 have been shown to block the
interaction between these molecules and restore antitumor
immunity within the TME [9, 10].
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Another mechanism of dampened immune response
that is thought to predominately exert its effects in
secondary lymphoid organs, as opposed to within the
TME, involves cytotoxic T lymphocyte-associated protein
4 (CTLA-4) expression on T cells. CTLA-4 is a receptor
exclusively expressed on T cells that binds to CD80 (B7.1)
and CD86 (B7.2) on antigen-presenting cells [11]. T cell
inhibition via this receptor occurs through multiple mech-
anisms. By outcompeting CD28 for binding to B7.1 and
B7.2, CTLA-4 can prevent the co-stimulation necessary to
generate and maintain T cell activation. Additionally,
evidence suggests that expression of CTLA-4 on Tregs
is important in T cell inhibition [12]. Antibodies to
CTLA-4 have been shown to block the interaction be-
tween CTLA-4 and its ligands, restoring the function
of T cells in the antigen-presenting compartment [13].
Clinical development of monoclonal antibodies that
block CTLA-4 and PD-1 have been major advances in
cancer immunotherapy. Ipilimumab, an antagonist mono-
clonal antibody (mAb) to CTLA-4, was first approved by
the Federal Drug Administration.
(FDA) for treatment of patients with advanced melan-
oma in 2011. Pembrolizumab and nivolumab are both
antagonist mAbs to PD-1 and were FDA approved in
2014. The ability of these checkpoint inhibitors to in-
duce durable complete and partial tumor responses
has ushered in a new era for the treatment of patients
with advanced melanoma. The high therapeutic index
of pembrolizumab and nivolumab has prompted their
study in the adjuvant setting in patients with resected
high-risk melanoma, both in combination with each
other as well as with other novel immunotherapy agents,
in patients with advanced disease. Research is ongoing
to identify biomarkers that can guide the selection of
immunotherapy for individual patients. All of these
approaches hold promise for further improvement in
the outcomes of patients with melanoma.
Anti-CTLA-4 therapy
Ipilimumab demonstrated clinical activity in early phase
trials [14–16] and was approved by the FDA following
the release of phase III data, which showed a signifi-
cantly improved OS relative to the glycoprotein 100
(gp100) peptide vaccine in previously treated melanoma
patients [17]. Median OS in patients receiving ipilimu-
mab plus gp100 and ipilimumab alone were 10.0 and
10.1 months, respectively, versus 6.4 months in those
that received gp100 alone. The more striking findings
from this study were the ipilimumab 1- and 2-year OS
rates for the ipilimumab-alone arm, of 45.6 % and
23.5 %, respectively, as well as similar rates for the ipili-
mumab plus gp100 arm. The 1-year OS rate was higher
than had previously been reported using any other ex-
perimental regimen for patients with untreated advanced
melanoma. In a second phase III trial, where advanced
melanoma patients were randomized to ipilimumab plus
dacarbazine versus dacarbazine alone, median OS was
superior in those who received ipilimumab (hazard ratio
(HR) for death was 0.72, P <0.001) [18]. However, the
combination of ipilimumab plus dacarbazine has not been
accepted as a standard approach due to the increased risk
of hepatotoxicity coupled with only a relatively modest in-
crease in clinical activity over ipilimumab alone.
Pooled data from 10 prospective and two retrospective
studies on ipilimumab-treated patients with advanced
melanoma confirmed that long-term survival is possible
[19]. The Kaplan–Meier survival curve of treated pa-
tients reached a plateau at 3 years with 22 % of patients
alive. Follow-up was extended to 10 years and it was
suggested that durable OS with ipilimumab could be
achieved. Subset analyses showed slightly better survival
in patients who were treatment naive, but no substantial
difference in survival was observed for patients treated
with ipilimumab at 3 mg/kg compared to 10 mg/kg dose
levels. The question of a difference in efficacy based on
dose level is currently being tested in a randomized
phase III trial of ipilimumab 3 mg/kg versus 10 mg/kg in
patients with metastatic melanoma (NCT01515189).
Tremelimumab, another mAb targeting CTLA-4,
displayed activity in a phase II study with an objective
response rate (ORR) of 9.8 % and 9.3 % in groups re-
ceiving 10 mg/kg every month and 15 mg/kg every
3 months, respectively [20]; the respective 12-month
OS rates were 32 % and 46 %. However, a randomized
phase III study of tremelimumab versus chemotherapy
failed to demonstrate a survival advantage [21]; never-
theless, data from this open-label study may have been
affected by crossover of patients in the chemotherapy
arm to ipilimumab, possibly confounding any potential
survival difference. Evaluation of tremelimumab’s activity
in combination with other agents is ongoing (discussed
below).
While ipilimumab increases immune activity against
tumor cells, it can also break immune tolerance to self
and cause autoimmune side effects. Such immune-related
adverse events (irAE) most commonly manifest as derma-
titis, colitis, hepatitis, hypophysitis, and thyroiditis [17]. A
meta-analysis (in subjects with various malignancies in-
cluding melanoma) calculated an overall incidence of
irAEs in 72 % of ipilimumab-treated patients, with a 24 %
incidence of high-grade adverse events [22]. Fortunately,
irAEs are responsive to corticosteroid therapy or other im-
mune suppressive agents and tumor responses can occur
even after treatment is stopped to initiate immunomodu-
latory therapy [17, 23]. Further, distinctive to checkpoint
inhibitor therapies, approximately 10 % of patients who
receive ipilimumab will initially experience ‘pseudopro-
gression’, wherein tumors appear to grow larger or new
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lesions develop, likely due to enhanced immune ef-
fector cell infiltration, and only subsequently exhibit
tumor shrinkage. These adverse events and response
characteristics led to the development of the irAE tox-
icity designation and immune-related response criteria
for adequate characterization of the effects of ipilimumab
treatment [24].
Anti-PD-1/PD-L1 therapy
Soon after the development of ipilimumab, data describing
the clinical activity of the anti-PD-1 mAb nivolumab in
patients with advanced malignancies emerged [25, 26]. In
patients with advanced melanoma, non-small cell lung
cancer (NSCLC), and renal cell cancer, objective responses
were seen in 17–34 % of patients with median response
durations of 13–24 months. Nivolumab also appeared to
have a favorable adverse event profile, with treatment-
related grade 3–4 toxicities typically occurring in less than
15 % of patients [26, 27]. OS rates for patients with melan-
oma were 62 % at 1 year, 43 % at 2 years, and 41 % at
3 years [27, 28]. The phase I trial of the anti-PD-1 mAb
pembrolizumab (KEYNOTE-001) also showed strong
clinical activity [29]. Pembrolizumab produced durable
responses in both ipilimumab-naive and previously
treated patients with melanoma with an ORR of 33 % [30].
Median duration of response had not yet been reached,
with a majority of patients continuing on active therapy.
Subsequent trials confirmed the efficacy of both nivo-
lumab and pembrolizumab in patients with advanced
melanoma. Weber et al. [31] reported on the random-
ized phase III trial of nivolumab versus investigator’s
choice chemotherapy in patients with melanoma whose
disease had progressed after ipilimumab and a BRAF in-
hibitor if the tumor contained a BRAF V600 mutation
(Checkmate-037). The study met its primary endpoint of
superior ORR in the nivolumab group, which was
31.7 %, compared to an ORR of 10.6 % with chemotherapy.
At the time of the analysis, 87 % of responses were ongoing.
The co-primary endpoint of improved OS has not yet been
reported. In the randomized phase II trial of pembrolizu-
mab compared to physician’s choice of chemotherapy in a
similar patient population, superior clinical activity was also
shown with pembrolizumab (KEYNOTE-002) [32]. The
ORRs were 25 % and 21 % for the 10 mg/kg and 2 mg/kg
dose levels of pembrolizumab, respectively, and 4 % for
chemotherapy. Median progression-free survival (PFS) was
5.6 and 5.4 months for the pembrolizumab arms versus
3.6 months for the chemotherapy arm. Crossover from
chemotherapy to pembrolizumab was permitted, confound-
ing the OS assessments.
IrAEs and other treatment-related adverse events can
be seen with anti-PD-1 therapies, although rates of se-
vere events (grade 3–5) have been lower than those
seen with ipilimumab, ranging from 8–16 % of patients
treated with either pembrolizumab or nivolumab [19,
26, 33]. The most common reported treatment-related
adverse events have been fatigue, pruritus, rash, arth-
ralgia, nausea, diarrhea, and hypothyroidism. Severe
cases of colitis, dermatitis, pneumonitis, and hepatitis
have been typically reported in 1 % or less of patients.
Severe irAEs can be managed by holding or discontinu-
ing the anti-PD-1 agent and administering high-dose
corticosteroids followed by other immune modulatory
agents if side effects are not quickly controlled.
Experience with anti-PD-L1 antibodies as monotherapy
in patients with advanced melanoma has been limited.
One out of eight melanoma patients on the phase I trial of
durvalumab (MEDI4736) achieved a partial response [34].
Data from the phase I trial of atezolizumab (MPDL3280A)
in locally advanced or metastatic melanoma patients
showed an ORR of 26 % as well as several patients with
delayed antitumor activity that was not included in the
ORR [35]. Grade 3–4 adverse events (regardless of attribu-
tion) were seen in 33 % of patients, which included hyper-
glycemia (7 %) and transaminitis (7 %). No cases of grade
3–5 pneumonitis were observed.
Anti-PD-1 therapy versus ipilimumab
Anti-PD1 therapy has now been compared head-to-head
with ipilimumab in the first line setting in patients with
metastatic melanoma. KEYNOTE-006 was a phase III
trial comparing standard ipilimumab to pembrolizumab
at 10 mg/kg every 2 or every 3 weeks in patients with
melanoma who were naive to checkpoint inhibitor therapy
[36]. ORR was similar for both pembrolizumab schedules
(33.7 % for every 2 weeks and 32.9 % for every 3 weeks) but
clearly higher than the ORR with ipilimumab (11.9 %); the
corresponding 6-month PFS rates were 47.3 %, 46.4 %, and
26.5 %, respectively. Further, 1-year OS was higher with
pembrolizumab (64.8–74.1 % vs. 58.2 % for ipilimumab)
and the emergence of severe treatment-related adverse
events was lower in patients receiving pembrolizumab
compared to ipilimumab (10.1–13.3 % vs. 19.9 %).
The Checkmate-067 study was a randomized phase III
trial of ipilimumab monotherapy compared to nivolumab
monotherapy or the combination of nivolumab and
ipilimumab in patients with advanced melanoma who
were naive to immune checkpoint inhibitor therapy [37];
the ORR was 43.7 % with nivolumab compared to 19.0 %
with ipilimumab. A longer PFS (HR, 0.57; P <0.001;
co-primary endpoint) and lower toxicity were seen
with nivolumab monotherapy as well. Data on OS has
not yet been reported. Thus, the data from KEYNOTE-
006 and Checkmate-067 confirm the clinical superiority of
anti-PD-1 therapy over anti-CTLA-4 therapy in patients
with advanced melanoma.
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Immune checkpoint blockade for melanoma brain
metastases (MBM)
Initial data from the phase III trial of ipilimumab with or
without the gp100 vaccine and an ipilimumab expanded
access program suggested clinical activity in a subset of
patients with MBM without additional toxicities [17, 38].
This led to the phase II study of ipilimumab in patients
with melanoma with previously untreated brain me-
tastases, which included a cohort of asymptomatic,
non-steroid-dependent patients and a cohort of symp-
tomatic patients requiring corticosteroids [39]. In the
first cohort, ipilimumab led to an intracranial ORR of
16 % and an intracranial disease control rate of 25 %.
While median OS was short (7.0 months), 24 % of patients
were alive at 2 years, indicating long-term survival may
also be possible in a subset of patients with MBM treated
with ipilimumab. In the cohort of patients with symptom-
atic MBM requiring steroids, the intracranial ORR and
disease control rates were notably lower (5 % and 10 %,
respectively), as were the median OS (3.7 months) and
2-year OS (10 %) rates. Similar irAEs were seen in this
MBM study compared to other ipilimumab studies. The
most common events were diarrhea, rash, pruritus, and el-
evated serum transaminase levels. Infrequent headaches,
dizziness, brain hemorrhage, and brain edema were also
reported; however, the low incidence suggests most were
probably related to the central nervous system (CNS) dis-
ease rather than increased toxicity from ipilimumab.
As with ipilimumab, anti-PD-1 studies permitted enroll-
ment of melanoma patients with treated brain metastases,
but this has generally represented less than 10 % of the
total accrued population. Preclinical data has suggested a
potential role for the treatment of active MBM with anti-
PD-1 therapy [40]. However, it is not clear if CNS penetra-
tion of the monoclonal antibodies is possible or required
to generate antitumor immune responses with this class of
therapy. Early data from an ongoing phase II study of
pembrolizumab in patients with active MBM was reported
at the ASCO 2015 General Meeting [41]. Out of 12
evaluable patients, three patients had intracranial par-
tial response (one of these subjects had received prior
ipilimumab). Two additional patients had stable intra-
cranial disease. The three partial responses were durable
for 7+, 6+, and 3+ months at the time of the report. There
were no significant treatment-related CNS adverse events
noted.
Adjuvant therapy for resected melanoma
Five-year survival rates in patients with resected stage III
melanoma have ranged from 70 % in patients with stage
IIIA disease to as low as 39 % in patients with stage IIIC
disease [42]. The role for adjuvant systemic therapy in
this setting and in cases of completely resected stage IV
melanoma has been studied in numerous trials. Both
high-dose IFN-alpha-2b and pegylated IFN-alpha-2b
have demonstrated improved relapse-free or disease-free
survival in randomized clinical trials and are approved
by the FDA for use in this setting [43, 44]. However,
improvement in OS has been inconsistent across trials
[45]. More recently, biochemotherapy was shown to yield
significantly longer relapse-free survival compared to
high-dose IFN in a randomized phase III clinical trial
conducted by the Southwest Oncology Group (S0008)
[46]; however, no difference was seen in OS and biochem-
otherapy was associated with a higher severe toxicity rate.
The clinical activity and tolerability of checkpoint in-
hibitors in patients with advanced melanoma provides
a rationale for investigation in the adjuvant setting.
Ipilimumab has now been studied in two randomized
phase III trials compared to placebo (EORTC 18071) or
high-dose IFN (ECOG 1609). In the EORTC 18071 trial,
patients with resected stage III cutaneous melanomas
were randomized to ipilimumab 10 mg/kg or placebo
every 3 weeks for four doses, then every 3 months for
up to 3 years [47]. Results showed improved median
recurrence-free survival of 26.1 months with ipilimumab
compared to 17.1 months with placebo (HR, 0.75; P =
0.0013). In subgroup analyses, patients with microscopic
lymph node disease or ulcerated primary lesions demon-
strated the most benefit. Also important to note was the
high rate of grade 3–5 irAEs seen in patients receiving
ipilimumab in this study (43 % vs. 2 % with placebo).
These included five treatment-related deaths (colitis n = 3,
myocarditis n = 1, and multiorgan failure with Guillan–
Barre syndrome n = 1), despite management with immu-
nomodulatory therapy. OS data is not yet mature. While
this data is provocative, and has led to the recent FDA ap-
proval of ipilimumab for patients with resected stage III
melanoma, it is as yet unclear whether the reduction in re-
currence rate with ipilimumab represents an improvement
over adjuvant IFN therapy and whether this benefit will
translate into an improvement in OS. The former question
is being addressed by the ongoing E1609 study, which ran-
domized patients with resected stage III–IV melanoma to
ipilimumab 10 mg/kg or 3 mg/kg or high-dose IFN [48].
The study completed accrual of more than 1,500 patients
in the summer of 2014 and is pending analysis for primary
endpoints of relapse-free survival and OS. Long-term
survival data from both of these adjuvant studies will
ultimately be necessary in order to determine the true
impact of adjuvant ipilimumab therapy.
PD-1 inhibitors have proven to be less toxic and more
active than ipilimumab in patients with established, unre-
sectable metastatic melanoma [36, 37]. Given the favorable
therapeutic index, there is much interest in developing
this class of therapies as adjuvant treatment for patients
with high-risk resected melanoma. Results from a phase
I trial of nivolumab plus a multi-peptide vaccine in 33
Redman et al. BMC Medicine  (2016) 14:20 Page 4 of 11
patients with resected stage IIIc or IV melanoma showed
a relatively low relapse rate (30 %) during a median
follow-up period of 32.1 months from trial enrollment.
Median relapse-free survival was estimated to be
47.1 months [49]. Phase III trials with nivolumab and
pembrolizumab in patients with resected stage III and
IV melanoma are currently underway. These include
Checkmate-238, comparing ipilimumab 10 mg/kg to nivo-
lumab 3 mg/kg, which completed accrual in September of
2015; the EORTC 1352 (KEYNOTE-054) protocol, com-
paring pembrolizumab (200 mg flat dose) to placebo,
which is actively accruing patients; and the SWOG S1404
protocol, comparing pembrolizumab (200 mg flat dose) to
high-dose IFN, which is also actively accruing patients
(NCT02506153).
Anti-PD-1/PD-L1 combination immune therapy strategies
Anti-PD-1/PD-L1 plus anti-CTLA-4
Preclinical murine studies verified the hypothesis that, in
light of their distinct mechanisms, combining CTLA-4
and PD-1 blockade could augment antitumor activity be-
yond that of either strategy alone. Combination therapy
increased the degree of tumor response and was associ-
ated with greater numbers of effector T cells and less
Tregs in the TME in murine models involving syngeneic
implants of either colon cancers or melanoma [50]. A
phase I trial of nivolumab plus ipilimumab in patients
with advanced melanoma demonstrated an ORR of 43 %
and 1- and 2-year OS rates of 85 % and 79 %, respect-
ively [51, 52]. The rate of grade 3–4 treatment-related
adverse events was substantially higher (>60 %) com-
pared to the rates previously seen with anti-CTLA-4 or
anti-PD-1 monotherapy. However, these events were
similar to those seen with ipilimumab monotherapy and
were also manageable with early institution of high-dose
corticosteroids or other immune modulatory agents.
Subsequently, two randomized studies (Checkmate-069
and Checkmate-067) were conducted to compare com-
bined immunotherapy with nivolumab plus ipilimumab
to immune checkpoint inhibitor monotherapy. The
Checkmate-069, a double-blind phase II trial, random-
ized patients to ipilimumab 3 mg/kg plus nivolumab
1 mg/kg or placebo every 3 weeks, followed by nivolu-
mab 3 mg/kg or placebo every 2 weeks until disease
progression or toxicity requiring study withdrawal [53].
In patients with BRAF-wildtype tumors, the ORR was
61 % in the group that received nivolumab plus ipilimu-
mab, compared to 11 % in the ipilimumab plus placebo
group. Median PFS was 4.4 months in the ipilimumab
monotherapy group, whereas median PFS was not reached
for the combination group at the time of analysis. There
were 16 patients (22 %) with complete responses in
the combination group, and none in the ipilimumab-
monotherapy group. A subset of patients with BRAF
mutant tumors were observed to have similar ORR
and PFS to those in the larger study, suggesting that
tumor BRAF status has no effect on response to checkpoint
inhibitor therapy. This favorable data clearly established
that combination therapy produced superior antitumor
efficacy to ipilimumab in patients with BRAF-wildtype
melanoma and led to the FDA approval of the combination
for this patient population in October 2015.
As mentioned earlier, the Checkmate-067 trial was a
three-arm, double blind, phase III trial that randomized
patients to nivolumab 3 mg/kg every 2 weeks or nivolumab
1 mg/kg every 3 weeks plus ipilimumab 3 mg/kg every
3 weeks for four doses, followed by nivolumab 3 mg/kg
every 2 weeks or ipilimumab 3 mg/kg every 3 weeks for
four doses [37]. While the study was not preplanned for a
statistical comparison between nivolumab plus ipilimumab
versus nivolumab monotherapy, the data provides insight
into how these two strategies compare to each other. The
ORR was 57.8 % in patients receiving the combination ther-
apy compared to 43.7 % in patients receiving nivolumab
monotherapy. Response was independent of tumor BRAF
mutational status. At the time of publication, OS data had
not yet matured; however, overall tumor shrinkage was
greater (51.9 % vs. 34.5 %) and median PFS was longer in
those patients receiving the combination compared to nivo-
lumab monotherapy (11.5 months vs. 6.5 months; HR, 0.74;
95 % confidence interval, 0.60–0.92).
The results from the Checkmate-069 and -067 studies
establish that the combination produces impressive anti-
tumor activity and suggests that all of the antitumor
effects of immunotherapy are not subsumed in the activity
of single agent PD-1 blockade. However, the combination
of nivolumab + ipilimumab also produces a clear increase
in severe treatment-related adverse events. In Checkmate-
069, the nivolumab plus ipilimumab group had a grade
3–5 adverse event rate of 54 % compared to a rate of
24 % observed in the ipilimumab-alone group [53]. In
Checkmate-067, grade 3–4 adverse events were seen at
a rate of 55 % in the nivolumab plus ipilimumab group,
compared to 16 % in the nivolumab group and 27 % in
the ipilimumab group [37]. While there were three re-
ported deaths in the combination therapy group that
were attributable to checkpoint inhibitor therapy in the
phase II trial [53], there were none in the phase III trial.
Similar to checkpoint inhibitor monotherapy, timely
recognition of irAEs and treatment with immunomodu-
lators can control these side effects in most patients re-
ceiving the combination. More importantly, stopping
treatment does not preclude derivation of benefit from
treatment. While 36 % of patients had treatment dis-
continuation on Checkmate-069, 67 % of these patients
had an objective response that continued on past dis-
continuation of therapy [37, 53].
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In light of the high toxicity profile of nivolumab plus
ipilimumab combination despite its clinical activity, al-
ternative combination strategies are now being explored,
including a randomized phase II sequencing trial of
nivolumab followed by ipilimumab versus ipilimumab
followed by nivolumab in patients with advanced melan-
oma (Checkmate-064) [54]; the cumulative ORRs at
week 25 were 47.7 % and 22.6 %, respectively, suggesting
higher clinical activity in patients who receive nivolumab
first. Unfortunately, the cumulative rates of grade 3–5
treatment-related adverse events remained high with
both sequencing approaches (50 % and 43 %, respectively).
Combination of pembrolizumab with a lower dose of
ipilimumab (1 mg/kg) is also currently being studied
in advanced melanoma patients enrolled in the KEYNOTE-
029 trial. Preliminary data showed antitumor activity and
perhaps less toxicity [55]. Dose expansion of this combin-
ation in patients with melanoma is ongoing with results
pending. In a comparable approach, the anti-PD-L1 mAb
durvalumab is being combined with the CTLA-4 mAb
tremelimumab in a phase I trial (NCT02537418).
Anti-PD-1 in combination with cytokine therapy
The clinical activity of combination anti-PD-1 and anti-
CTLA-4 therapies provides proof of principal that efficacy
seen with anti-PD-1 monotherapy can be enhanced by the
addition of other non-redundant immunotherapies. Past
studies combining cytokines with ipilimumab, such as
IFN-alpha-2b and granulocyte macrophage-colony stimu-
lation factor (GM-CSF), have suggested enhanced clinical
activity, which provides merit for combining such agents
with PD-1 pathway blockers. A single center phase I/II
study of pegylated IFN (1–3 μg/kg weekly) in combination
with standard ipilimumab dosing showed an ORR of 47 %
and 1-year OS of 56 % [56]. In a randomized phase II
study of ipilimumab (10 mg/kg) with or without GM-CSF,
the ORRs were similar (15.5 % vs. 14.8 %, respectively),
but a significantly longer OS was demonstrated in the
combination group (1-year OS rate of 68.9 % vs. 52.9 %,
P = 0.01) [57]. Interestingly, fewer grade 3–5 toxicities
were observed in the combination group compared to
ipilimumab monotherapy (45 % vs. 58 %). Both of these
studies have led to investigation of cytokines in combin-
ation with anti-PD-1-based regimens.
The combination of pegylated IFN and pembrolizumab
has now been investigated in two separate clinical trials
(NCT02112032 and NCT02089685). Preliminary results
of the single center study were presented in abstract form
at the 2015 ASCO General Meeting [58]. In this phase I
trial, three dose levels of weekly pegylated IFN (1, 2, and
3 μg/kg weekly) were combined with pembrolizumab at
2 mg/kg every 3 weeks. The combination was reasonably
tolerated in the first 12 patients and clinical activity was
seen in the six evaluable patients. The second trial is
KEYNOTE-029, where it was studied in patients with ad-
vanced melanoma and renal cell carcinoma; data from this
study has not been published. With regards to GM-CSF, a
randomized phase III intergroup trial of nivolumab plus
ipilimumab with or without sargramostim (EA6141) is
currently recruiting subjects with advanced melanoma
and should provide more guidance (NCT02339571).
Anti-PD-1/PD-L1 in combination with novel immune agents
Talimogene laherparepvec (T-VEC) is an oncolytic virus
(modified herpes simplex virus) that expresses GM-CSF,
which is injected directly into the tumor to generate an
antitumor immune response. A randomized phase III
study (OPTiM trial) in patients with unresectable stage
IIIb–IV melanoma comparing intralesional T-VEC ther-
apy to subcutaneous GM-CSF therapy demonstrated an
overall durable response rate of 16.3 % (2.1 % for GM-CSF
arm) [59]. This included tumor regression in injected
tumor sites as well as occasional regression in non-
injected tumor sites. While OS was not significantly
improved, there appeared to be a strong trend toward
greater benefit in those patients receiving T-VEC relative
to GM-CSF alone, particularly in those with regional
disease only. The application of T-VEC therapy for
local immune stimulation in a combination immune
checkpoint blockade could provide enhanced clinical
activity. The combination of T-VEC with ipilimumab is
being studied in an ongoing phase Ib/II trial of patients
with metastatic melanoma and at least one injectable
lesion [60]. Early data has demonstrated an ORR of
56 % (33 % complete response rate) with a median PFS
of 10.6 months. OS at 12 and 18 months was 72.2 %
and 67 %, respectively; however, these results are likely
influenced by the inclusion of stage III patients in the
study. T-VEC is also being studied in combination with
anti-PD-1 therapy. A randomized, open label trial of T-
VEC plus pembrolizumab versus pembrolizumab alone
is actively enrolling patients with unresectable stage
IIIB–IV melanoma and at least one injectable lesion
(NCT02263508).
Another promising immunotherapy target for combin-
ation strategies is indoleamine 2,3-dioxygenase 1 (IDO1),
which is upregulated in malignant cells and myeloid-
derived suppressor cells and converts tryptophan to
kynurenine, leading to immune suppression in the TME
[61, 62]. While monotherapy with IDO1 inhibition has
not demonstrated robust clinical activity [63], promising
results have been demonstrated with the combination of
the IDO1 inhibitor epacadostat (INCB024360) and ipili-
mumab in patients with advanced melanoma. From the
phase I trial, a dose of epacadostat up to 50 mg twice
daily in combination with standard ipilimumab was gen-
erally well tolerated and with an ORR of 31 % (10 out of
32 immunotherapy-naive patients) [64]. In vivo studies
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have also demonstrated a synergistic effect when com-
bining IDO1 inhibition with PD-1 blockade [65]. A phase
I/II trial of pembrolizumab plus epacadostat in multiple
malignancies including melanoma is currently underway.
Preliminary data presented at the 2015 SITC general
meeting showed objective responses in four out of seven
patients with melanoma evaluable at the time of the re-
port. Across all malignancies in this study, there were
few grade 3 adverse events and no grade 4 events [66].
In addition, clinical trials with epacadostat in combin-
ation with other anti-PD-1/PD-L1 therapies (including
nivolumab, durvalumab, and atezolizumab) are currently
enrolling patients.
Multiple novel immune checkpoint agonists and an-
tagonists as monotherapy and in combination are in
development, including stimulatory mAbs directed at
4-1BB, OX40, CD27, and GITR on T cells in the TME.
Of these targets, several are already planned for combin-
ation phase I/II studies with PD-1 pathway inhibitors,
such as the 4-1BB agonist PF-05082566 plus pembroli-
zumab (NCT02179918), the OX40 ligand fusion pro-
tein MEDI6383 in combination with durvalumab
(NCT02221960), and the CD27 agonist varililumab in
combination with nivolumab (NCT02335918). Blockade
of immune suppressive targets, such as LAG-3 and
TIM-3, may also hold promise alone or in combination
with PD-1 pathway inhibitors. Indeed, preclinical data
have shown that in vivo co-inhibition or knock-out of
LAG-3 and PD-1 demonstrated robust immune activation,
tumor rejection, and abrogation of self-tolerance [67, 68].
Further implying a role for anti-LAG-3 and anti-PD-1
combination therapy, a recent study on banked melanoma
tumor samples showed the LAG-3 gene to be overex-
pressed in PD-L1 positive tumors [69]. The anti-LAG-3
mAb BMS-986016 is currently being studied in a phase I
trial as monotherapy and in combination with nivolumab
in patients with advanced solid tumors (NCT01968109).
These new checkpoint agents may eventually prove to be
effective alternatives to ipilimumab for combination with
the anti-PD-1 blockade as upfront therapy or after pro-
gression with anti-PD-1/PD-L1 monotherapy.
Biomarkers
The development of predictive biomarkers for immuno-
therapies in melanoma has been an area of great research
interest. Past studies examining biomarkers associated
with clinical benefit from high-dose IL-2 have yielded sev-
eral potential strategies, including circulating vascular
endothelial growth factor and fibronectin levels or T cell
gene expression patterns on tumor biopsies [70, 71]. How-
ever, these have not been validated in prospective trials. In
this era of checkpoint inhibitor therapy, identification of a
population that benefits as much from anti-PD-1 mono-
therapy as combination anti-PD-1 plus ipilimumab would
be useful as it could spare patients the increased risk of se-
vere adverse events from combination therapy. Research
into predictive biomarkers for anti-PD-1-based therapies
has largely focused on PD-L1 expression, but other prom-
ising strategies are now emerging.
PD-L1 expression
Data from the phase I study of nivolumab suggested a
potential role for use of tumor PD-L1 immunohisto-
chemistry (IHC) as a predictive biomarker for anti-PD-1
therapy [26]. Nine of 25 patients (36 %) with PD-L1-
positive disease demonstrated an objective response to
nivolumab, whereas none of the 17 PD-L1-negative
tumor patients had an objective response. Subsequent
studies have demonstrated higher response rates with
anti-PD-1 therapies in patients whose tumors are PD-L1
positive [72]. However, objective responses in patients
with PD-L1 negative tumors have been observed in most
studies with ORRs ranging from 11–20 % and as high as
41.3 % in Checkmate-067 [37]. Therefore, refraining from
the use of anti-PD-1/PD-L1 agents in patients whose
tumors test negative for PD-L1 status would potentially
prevent access to an effective therapeutic strategy in a
large number of patients. Furthermore, the use of PD-L1
as a predictive biomarker is complicated by the lack of
uniformity in the antibody used for PD-L1 detection and
thresholds for cutoff of PD-L1 positive and negative status
across studies [73]. For example, the PD-L1 assay devel-
oped as a biomarker for pembrolizumab studies uses an
antibody against the 22C3 region of PD-L1 and a ‘propor-
tional score’ of ≥1 % (melanoma) for PD-L1-positive dis-
ease, which has been observed in 80 % of melanoma
tumors [32, 36]. A similar PD-L1 assay for nivolumab uses
an antibody targeting the 28-8 region of PD-L1 for IHC
and uses a cutoff of 5 % (1 % and 10 % cutoff points have
also been studied), where 24–50 % of melanoma tumors
test positive [31, 37].
Despite these limitations, the use of PD-L1 IHC is im-
portant for stratification of patients on anti-PD-1/PD-L1
therapy trials. It may also play a role in the selection of
immunotherapy strategies in patients with melanoma
and other malignancies. Data on patients with advanced
NSCLC from the phase I study of pembrolizumab
(KEYNOTE-001) and the phase III study of nivolumab
(non-squamous only; Checkmate-057) is probably the
strongest so far for clinical application of PD-L1 testing.
From the KEYNOTE-001 study, the ORR was enriched
3- to 4-fold and OS was not reached after a median
follow-up of 10.9 months in NSCLC patients with a
PD-L1 expression proportional score of ≥50 % [74].
Similarly, in Checkmate-057, PD-L1-positive patients
(5 % cutoff) showed significant improvement in OS with
nivolumab over docetaxel (HR, 0.43; P <0.001), which
was not observed in PD-L1-negative patients [75]. With
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regards to melanoma, the Checkmate-067 study dem-
onstrated similar PFS between nivolumab monotherapy
and nivolumab plus ipilimumab combination arms (median
PFS was 14 months in both) in PD-L1-positive patients
[37]. However, the ORR was greater with the nivolumab
plus ipilimumab combination therapy compared to nivolu-
mab monotherapy (72.1 % vs. 57.5 %, respectively) in PD-
L1-positive patients and OS data is not yet mature. As such,
the value of tumor PD-L1 expression in choosing combin-
ation versus monotherapy remains to be determined.
In order for PD-L1 status to move forward as an ef-
fective predictive biomarker, PD-L1 assays will likely
need to be standardized and associations confirmed in
prospective studies. Because of the intra-tumor and
patient heterogeneity of PD-L1 status and the inducible
nature of PD-L1 [73], additional biomarker approaches
will likely be needed to adequately predict likelihood of
response to checkpoint inhibitors.
Emerging biomarker strategies associated with anti-PD-1/
PD-L1 therapy
Tumeh et al. [76] demonstrated that response to anti-PD-
1 therapy appears to rely on a pre-treatment presence of
PD-1- and PD-L1-expressing cells at a close interface, as
well as the presence of CD8+ TILs. This study describes
what are likely the components of phenotypic patterns of
immune interaction governing the immune resistance of
tumors along this spectrum. The activity of TILs is in-
cluded in these analyses, as it has been shown that their
secretion of IFN-gamma can induce PD-L1 expression in
tumor cells [77, 78]. Analysis of gene expression in re-
sponders to pembrolizumab from the KEYNOTE-001
study revealed an increase in the expression of IFN-
gamma-associated genes [79].
Tumeh et al. [76] identified the presence of CD8+ TIL
in patients who responded to pembrolizumab and hy-
pothesized that this infiltrate would have a narrowed
repertoire of T cell receptors that enable a tumor-specific
immune response. Next generation sequencing of pre-
treatment tumor samples revealed a less diverse and more
clonal population of T cells [76]. Moreover, post-treatment,
biopsies revealed 10-fold greater T cell receptor clonal ex-
pansion when compared to pre-treatment biopsies. As pro-
posed by the authors, these data indicate that PD-1/PD-L1
expression may be an indirect marker of activated CD8+
TIL within the TME. It is this activity that may be driving
adaptive immune escape by tumors via the PD-1/PD-L1
axis and other mechanisms. Further, this presence seems to
correlate with response to anti-PD-1 therapy. These find-
ings provide a basis from which to hypothesize that
addition of ipilimumab to anti-PD-1 inhibitor therapy can
provide additional immune support in patients without
brisk CD8+ TIL infiltration.
Other works offer mutational burden and the presence
of neoantigens as a potential marker of response to anti-
CTLA-4 and anti-PD-1 therapies. A study of 64 melanoma
patients treated with ipilimumab or tremelimumab an-
alyzed the association of mutational load based on
tumor whole exome sequencing and clinical benefit
(disease control for at least 6 months) [80]. A signifi-
cant correlation between mutational load (>100 non-
synonymous somatic mutations) and clinical benefit
was seen. Furthermore, derivation of a neoepitope sig-
nature for major histocompatibility complex class I
presentation from this data was highly associated with
clinical outcome, providing a strong scientific explan-
ation for this observation. A similar study was recently
published [81], where tumor samples of 110 melanoma
patients treated with ipilimumab were analyzed via whole
exome sequencing. These data also demonstrated that
mutational and neoantigen loads were associated with
clinical benefit from ipilimumab. However, identified
neoantigens rarely recurred among patients. As the au-
thors suggest [78], larger cohorts will likely be required
to identify markers predictive of clinical benefit with
checkpoint inhibitor therapy in future studies. Interest-
ingly, a large-scale genetic study on banked tumor samples
of many different malignancies analyzed genes of TIL and
tumor cells [82], revealing neoantigen presence as a strong
predictor of cytolytic activity and highlighting several mu-
tations associated with less cytolytic activity than expected.
Another analysis of mutational burden has been associated
with clinical outcomes in patients with NSCLC treated
with pembrolizumab [83].
Further investigation into the relationship of PD-1/
PD-L1 expression, TIL presence, T cell repertoire, and
mutational burden should be aimed at creating a model
by which response to anti-PD-1/PD-L1-based therapies
can be predicted. In such a model, different profiles may
help select patients who will have optimal benefit with
anti-PD-1/PD-L1 monotherapy and/or direct towards
various combination approaches.
Conclusions
The introduction of checkpoint inhibitor immunotherapies
has ushered in a new era in the treatment of patients with
melanoma. Anti-CTLA-4- and anti-PD-1-based approaches
have expanded upon the successes seen with systemic IL-2
and can produce response rates above 50 % when ad-
ministered in combination. While the efficacy of these
new therapies is enhanced, the toxicity is less severe
than that seen with high-dose IL-2. The toxicities from
checkpoint immunotherapy represent a new class of
adverse events, termed irAEs, manageable with early
application of systemic corticosteroids or immunomod-
ulators and possible predictors of favorable PFS and OS
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[84]. Remarkably, immunosuppressive therapy does not
appear to dampen ongoing antitumor effects [85].
In evaluating response to these new therapies, there
appears to be a spectrum of patients ranging from those
in which blocking the PD-1/PD-L1 axis alone is effective
to those who respond better with the addition of CTLA-4
blockade and, finally, to those who do not respond to ei-
ther strategy. Novel immunotherapies are in the clinical
pipeline and will hopefully provide effective options for
those who do not respond to anti-PD-1-based combin-
ation approaches.
While the OS data from the Checkmate-067 study are
not yet mature, it is clear that the combination of anti-
CTLA-4 and anti-PD-1 therapy produces a better ORR
and median PFS, but also greater toxicity, than either
monotherapy. Therefore, a predictive model based on
multiple biomarkers will likely be needed to select pa-
tients who will require combination treatment regimens
with higher toxicity rates in order to maximize antitu-
mor responses. Despite early data identifying expression
of PD-L1 on tumor cells as being associated with response
to anti-PD-1/PD-L1 monotherapy, that characteristic
alone is not currently suitable for clinical decision-making
in patients with melanoma. While standardization of
PD-L1 assays will be useful, multiple biomarkers beyond
PD-L1 status will likely need to be incorporated in order
to achieve the precision required for guiding therapeutic
choices in individual patients. Likely candidates include
CD8+ T cell density and geographic associations with
PD-L1, IFN-gamma gene expression signatures, T cell
clonality, and mutational burden/neo-epitope signatures.
Sampling patient tumors in the pre-treatment setting for
tumor immune phenotypes or composite biomarker pro-
files is likely to become a standard process in immuno-
therapy planning for patients with melanoma and other
immune responsive tumors.
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